CVSA
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Covista Inc., formerly Adtalem Global Education Inc., is a healthcare education provider operating five accredited institutions in the United States and the Caribbean. The company is organized into three reportable segments: Chamberlain, Walden, and Medical and Veterinary. Chamberlain University offers degree and certificate programs in nursing and health professions, including the College of Nursing and College of Health Professions. Walden University provides degree and certificate programs in nursing, education, counseling, business, information technology, psychology, public health, social work, and criminal justice, utilizing its Tempo Learning modality for competency-based education. The Medical and Veterinary segment comprises the American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Covista serves working adults, career changers, and non-traditional students through on-campus and online delivery methods. The company partners with hospitals, healthcare providers, and technology firms such as Google Cloud and Hippocratic AI to integrate AI tools into clinical education and connect graduates to employment. Incorporated in 1987, Covista focuses on expanding access to healthcare careers and addressing workforce shortages in the U.S. and international markets.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Education & Training Services Homepage covista.com
Sector Consumer Defensive IR page investors.covista.com/overview/default.aspx
Tags
healthcare education, nursing education, medical education, veterinary medicine, online learning, competency-based education, workforce development, clinical training, adult education, postsecondary education, Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, Ross University School of Veterinary Medicine, College of Nursing, College of Health Professions, Tempo Learning, Covista Healthcare Workforce Index
Press page covista.com/news-research/press-releases

Metrics

Valuation  
Market cap $ 4.39B
Market cap (USD) $ 4.39B
P/E 16.51
PEG 0.43
P/BV 3.09
P/S 2.19
P/OCF 9.67
P/FCF 12.38
Dividend yield 0.14%
Turnover / mcap —
Returns  
ROE 17.5%
ROI 11.9%
ROIC 14.1%
Profit margin 12.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 38.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 35.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 114
Quality score 61.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 1.954B 1.788B 1.585B 1.451B 1.387B 1.112B 1.052B 1.24B 160.49M 1.81B 1.844B 1.91B 465.942M 415.4M 2.09B 2.182B 1.915B 1.461B 1.092B 933.473M 843.298M 781.304M 784.885M 679.579M 648.134M 568.177M 506.824M 420.635M
Net profit 251.566M 237.065M 136.777M 93.358M 317.705M 76.909M -85.334M 95.168M 33.769M 122.283M -3.166M 139.899M 134.032M 106.786M 141.565M 330.403M 279.909M 165.613M 125.532M 76.188M 43.053M 28.544M 58.061M 61.148M 67.055M 57.776M 47.781M 38.83M
Free cash flow 392.726M 287.572M 246.882M 165.9M -20.63M 143.535M 63.555M 140.107M 172.659M 178.97M 162.173M 114.4M 186.206M 149.73M 148.367M 272.264M 260.539M 175.482M 135.84M — 65.557M 44.649M 91.619M 54.489M 29.45M 10.666M 30.537M 9.748M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 124.66 127.23 68.21 34.34 35.97 35.64 31.15 45.05 48.1 37.95 — — — — — — — — — — — — — — — — — —
Price performance 12m -0.02 0.87 0.99 -0.05 0.01 0.14 -0.31 -0.06 0.27 — — — — — — — — — — — — — — — — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 173M 147M 158M 87M 65.9M 79M 100M 124M 143M 167M
↳ YoY growth +6.8% -15.4% +7.6% -44.9% -24.3% +19.8% +26.8% +23.9% +15.6% +16.3%
↳ 5y CAGR +8.8% +1.0% +3.5% -9.0% -16.5% -14.5% -7.4% -4.7% +10.5% +20.4%
Borrowings, current (USD) 0.00 3M 3M 3M 3M 0.00 — — 0.00 5.1M
Borrowings, non-current (USD) 125M 290M 398M 286M 1.07B 839M 695M 649M 553M 658M
Lease liabilities (USD) — — 0.00 228M 223M 228M 201M 199M 221M 243M
Cash and deposits (USD) 242M 431M 299M 501M 495M 347M 274M 219M 200M 406M
Intangible assets (USD) 414M 363M 418M 288M 276M 874M 812M 777M 765M 754M
Right-of-use assets (USD) — — 0.00 175M 169M 178M 175M 177M 191M 204M
Net debt (borrowings + leases - cash) (USD) -115M -138M 102M 16.3M 799M 720M 623M 629M 574M 499M
Cash flow detail
Operating cash flow (USD) 228M 239M 205M 108M 192M 10.4M 203M 296M 338M 470M
Purchases of property, plant and equipment (USD) -49M -66.5M -64.8M -44.1M -48.7M -31.1M -37M -48.9M -50.3M -77.7M
Change in receivables (cash effect) (USD) -100M -43.3M -27.7M -12.8M 13.3M -29.9M -37.6M -76.4M -80.8M -89.3M
Change in payables (cash effect) (USD) 755,000 9.96M 9.2M -6.34M 8.53M -15.7M 21.7M 18.3M 140,000 6.19M
Dividends paid (cash effect) (USD) -11.4M 0.00 0.00 — — — — — — —
Share buybacks (cash effect) (USD) -48.5M -137M -253M -137M -100M -120M -123M -262M -213M -240M
Interest paid (cash effect) (USD) -7.33M -11.5M -20.4M -20.2M -14.4M -107M -53.1M -57.8M -46.6M -44.8M
Income taxes paid (cash effect) (USD) -14.9M -8.37M -3.23M -12.4M -26.4M -94.4M -12.3M -31.5M -32.8M -13.6M
Share-based compensation (USD) 16.6M 14.5M 13.2M 14.6M 13.9M 22.6M 14.3M 25.9M 41.6M 41.2M
Operating cash flow before change in receivables (USD) 328M 282M 233M 121M 179M 40.3M 241M 372M 419M 560M
Free cash flow (OCF - PPE - intangibles) (USD) 179M 173M 140M 63.6M 144M -20.6M 166M 247M 288M 393M
Income detail
Total comprehensive income (USD) 107M -48.8M 101M 42.5M 78.2M 324M 93.4M 137M — —
Comprehensive income to owners (USD) 106M -47.6M 100M 42.9M 78.6M 324M 93.4M 137M — —
Provision for credit losses (USD) 19M 16.9M 19.1M 16.2M 6.26M 23.8M 29.4M 50.2M 61.3M 67.2M
Credit cost ratio (credit losses / average receivables) (%) 11.3% 10.6% 12.6% 13.2% 8.2% 32.9% 32.8% 44.8% 45.8% 43.3%
Reported Aug 28, 2019 Aug 28, 2019 Oct 30, 2019 Aug 18, 2020 Aug 19, 2021 Aug 11, 2022 Aug 10, 2023 Aug 6, 2024 May 7, 2026 Aug 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 29, 2026, Covista Inc. (“Covista”) issued a press release announcing its first quarter fiscal 2027 academic, operating and financial results. The press release is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Cautionary Disclosure Regarding Forward-Looking Statements Certain statements contained in this Form 8-K and related press release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements.

Investor Contact: Jeremy Cohen [email protected] Media Contact: Nick Lucido [email protected]

Covista Reports First Quarter Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS Guidance Total enrollment up 7.6% YoY Revenue up 10.7% YoY Diluted earnings per share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY Chief Financial Officer Robert Phelan announces planned retirement; will continue to serve until a successor is named FIRST QUARTER HIGHLIGHTS • Total student enrollment of 104,713, up 7.6% year-over-year, achieved 13th straight quarter of growth • Revenue of $511.5 million, up 10.7% year-over-year • Chamberlain University achieved 3rd straight quarter of total enrollment growth and achieved 17th straight quarter of pre-licensure BSN total enrollment growth • Walden University achieved 13th straight quarter of total enrollment growth, up 12.8% year-overyear, highest total enrollment in university history • Medical and Veterinary delivered total enrollment growth of 3.5% year-over-year • GAAP net income $67.4 million; adjusted EBITDA $131.2 million, up 17.1% year-over-year

CAPITAL ALLOCATION • Repurchased $84 million of shares in the first quarter • Net leverage of 0.5x as of Sep. 30, 2026 • Repriced our $510 million Term Loan B, reducing the interest rate margin by 25 basis points to SOFR plus 2.00%

INCREASED FISCAL YEAR 2027 GUIDANCE • Revenue in the range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year, and from a previous range of $2,050 million to $2,090 million • Adjusted earnings per share in the range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year, and from a previous range of $8.90 to $9.15

CHICAGO – October 29, 2026 /Businesswire/ Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal year 2027 results (ended Sep. 30, 2026). This quarter, the Company launched Purpose at Scale, its three-year strategy to train the next generation of healthcare professionals at industry-leading scale. Purpose at Scale is underpinned by operational excellence, platform extension, employer integration and a technology focus. “Purpose at Scale is delivering and all four pillars of the strategy are contributing to our momentum. Total enrollment grew for the 13th consecutive quarter, powering our double-digit revenue growth and continued margin expansion. On that strength, we are raising our fiscal 2027 guidance,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “The demand behind our strategy is durable, and Covista is critical infrastructure for American healthcare. We serve an urgent need in the communities where care matters most, and by doing that well, we are strategically positioned to create lasting value for our shareholders.”

Financial Highlights Selected financial data for the three months ended Sept. 30, 2026: • Revenue of $511.5 million increased 10.7% compared with the prior year • Operating income of $98.0 million, compared with $85.5 million in the prior year; adjusted operating income of $106.6 million, compared with $90.3 million in the prior year • Net income of $67.4 million, compared with $61.8 million in the prior year; adjusted net income of $75.8 million, compared with $64.9 million in the prior year • Diluted earnings per share of $1.95, compared with $1.67 in the prior year; adjusted earnings per share of $2.19, compared with $1.75 in the prior year • Adjusted EBITDA of $131.2 million, compared with $112.0 million in the prior year; adjusted EBITDA margin of 25.6%, compared with 24.2% in the prior year

Business Highlights • Covista's strategic nursing collaboration with Advocate Health began enrolling students through Chamberlain University in Wisconsin. Building on that successful launch, the relationship is expanding to Chamberlain's three Chicago-area campuses. • Chamberlain University opened its Cincinnati and Salt Lake City campuses. The Company also announced it will open its 27th campus in Nashville, which is expected to begin classes in January 2027. • Walden University launched four new programs this quarter. Programs introduced heading into the 2026 academic year have already enrolled more than 2,000 students, demonstrating Walden’s speed to market in high-demand fields. • Covista released new analysis showing that students at Ross University School of Medicine and American University of the Caribbean School of Medicine passed the United States Medical Licensing Examination® (USMLE®) Step 1 on their first attempt at rates comparable to or higher than U.S. MD students with similar MCAT scores in most score bands.1 • Covista’s performance and responsible business practices continued to earn national recognition, including TIME’s America’s Growth Leaders 2027 and World’s Best Companies 2026, and Newsweek’s America’s Greenest Companies 2027 and America’s Greatest Companies 2026.

Segment Highlights Chamberlain

$ in millions Revenue Operating Income Adj. Operating Income Adj. EBITDA Total Students (2)

Three Months Ended September 30, 2026 2025 % Change $192.4 $179.2 7.4% $26.7 $25.6 4.4% $26.7 $25.6 4.4% $37.6 $35.1 7.1% 40,351 39,846 1.3%

• Total student enrollment increased 1.3% compared with the prior year, driven by growth in prelicensure nursing.

Walden

$ in millions Revenue Operating Income Adj. Operating Income Adj. EBITDA Total Students (2)

Three Months Ended September 30, 2026 2025 % Change $216.7 $190.0 14.1% $63.6 $53.3 19.5% $65.0 $56.1 16.0% $71.9 $61.9 16.1% 58,881 52,216 12.8%

• Total student enrollment increased 12.8% compared with the prior year, driven by growth in healthcare and non-healthcare programs. Medical and Veterinary

$ in millions Revenue Operating Income Adj. Operating Income Adj. EBITDA Total Students (2)

Three Months Ended September 30, 2026 2025 % Change $102.5 $93.1 10.0% $22.3 $16.7 33.0% $22.3 $16.8 32.7% $27.4 $21.4 27.9% 5,481 5,297 3.5%

• Total student enrollment increased 3.5% compared with the prior year, driven by growth in both medical and veterinary.

Fiscal Year 2027 Outlook Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year. Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year.

Management Update Chief Financial Officer Robert Phelan has decided to retire from Covista after nearly seven years, as part of a planned transition. He will remain in this role until a successor is named, with no change in responsibilities. He will support the incoming Chief Financial Officer through a transition period. An active search is underway.

Conference Call and Webcast Information Covista will hold a conference call to discuss its first quarter fiscal year 2027 results today at 4:00 p.m. CT (5:00 p.m. ET). The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13762351. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com/. Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13762351, or visit the Covista investor relations website.

About Covista Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on LinkedIn, Instagram and YouTube.

Cautionary Disclosure Regarding Forward-Looking Statements Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to

any historical or current fact, which includes statements regarding Covista’s future growth. Forwardlooking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forwardlooking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP. 1.

Comparison using university and AAMC data. Data is based on students who matriculated between 2021-2023 and sat for the USMLE Step 1 as of August 2026. Not all matriculants sat for the USMLE Step 1 exam. Students must successfully matriculate, complete the Medical Sciences curriculum and pass a school approved Medical Sciences Comprehensive Exam to sit for the USMLE Step 1 exam. Represents total students attending sessions during each institution’s most recent enrollment period in Q1 FY 2027 and Q1 FY 2026.

Covista Inc. Consolidated Balance Sheets (unaudited) (in thousands) September 30, 2026 Assets: Current assets: Cash and cash equivalents Restricted cash Accounts and financing receivables, net Prepaid expenses and other current assets Total current assets Noncurrent assets: Property and equipment, net Operating lease assets Intangible assets, net Goodwill Other assets, net Total noncurrent assets Total assets Liabilities and shareholders' equity: Current liabilities: Accounts payable Accrued payroll and benefits Accrued liabilities Deferred revenue Current operating lease liabilities Current portion of long-term debt Total current liabilities Noncurrent liabilities: Long-term debt Long-term operating lease liabilities Deferred income taxes Other liabilities Total noncurrent liabilities Total liabilities Commitments and contingencies Total shareholders' equity Total liabilities and shareholders' equity

$

$

$

222,223 2,336 241,469 86,542 552,570 324,706 197,511 752,860 961,262 139,364 2,375,703 2,928,273

96,383 57,720 126,214 365,096 33,984 5,100 684,497

June 30, 2026

$

$

$

495,131 219,374 69,320 38,308 822,133 1,506,630

$

1,421,643 2,928,273

406,316 1,438 169,561 75,126 652,441 302,649 204,364 754,254 961,262 137,738 2,360,267 3,012,708

124,763 78,669 94,364 259,125 34,799 5,100 596,820 657,750 207,846 61,782 42,325 969,703 1,566,523

$

1,446,185 3,012,708

Covista Inc. Consolidated Statements of Income (unaudited) (in thousands, except per share data)

Revenue Operating cost and expense: Cost of educational services Student services and administrative expense Restructuring expense Total operating cost and expense Operating income Interest expense Other income, net Income from continuing operations before income taxes Provision for income taxes Income from continuing operations Discontinued operations: (Loss) income from discontinued operations before income taxes Benefit from income taxes (Loss) income from discontinued operations Net income and comprehensive income Earnings (loss) per share: Basic: Continuing operations Discontinued operations Total basic earnings per share Diluted: Continuing operations Discontinued operations Total diluted earnings per share Weighted-average shares outstanding: Basic shares Diluted shares

$

Three Months Ended September 30, 2026 2025 511,534 $ 462,288 220,759 192,585 163 413,507 98,027 (9,944) 1,416 89,499 (18,017) 71,482

200,767 175,734 310 376,811 85,477 (11,090) 2,486 76,873 (15,811) 61,062

$

(5,420) 1,365 (4,055) 67,427

$

747 23 770 61,832

$ $ $

2.11 (0.12) 1.99

$ $ $

1.69 0.02 1.71

$ $ $

2.07 (0.12) 1.95

$ $ $

1.65 0.02 1.67

33,951 34,573

36,111 37,057

Covista Inc. Consolidated Statements of Cash Flows (unaudited) (in thousands) Three Months Ended September 30, 2026 2025 Operating activities: Net income Loss (income) from discontinued operations Income from continuing operations Adjustments to reconcile net income to net cash provided by operating activities: Stock-based compensation Amortization of operating lease assets Depreciation Amortization of acquired intangible assets Amortization and write-off of debt discount and issuance costs Provision for credit losses Deferred income taxes Loss on disposals and impairments of property and equipment Loss (gain) on investments Changes in assets and liabilities: Accounts and financing receivables Prepaid expenses and other current assets Cloud computing implementation assets Accounts payable Accrued payroll and benefits Accrued liabilities Deferred revenue Operating lease liabilities Other assets and liabilities Net cash provided by operating activities-continuing operations Net cash used in operating activities-discontinued operations Net cash provided by operating activities Investing activities: Capital expenditures Proceeds from sales of marketable securities Purchases of marketable securities Net cash used in investing activities Financing activities: Proceeds from exercise of stock options Employee taxes paid on withholding shares Proceeds from stock issued under Colleague Stock Purchase Plan Repurchases of common stock for treasury Repayments under long-term debt obligations Payment of debt issuance costs Net cash used in financing activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period

$

$

67,427 4,055 71,482

$

61,832 (770) 61,062

8,181 7,018 10,862 1,394 660 22,402 8,798 — 218

8,293 7,216 10,296 2,805 1,145 14,883 54,413 2 (680)

(94,219) (10,788) (3,292) (13,536) (20,886) 13,025 107,928 10,548 (5,524) 114,271 (233) 114,038

(62,690) (29,841) (4,812) 1,378 (24,359) (12,287) 109,082 (4,317) (960) 130,629 (80) 130,549

(37,592) — — (37,592)

(16,023) 100 (100) (16,023)

— (16,203) 564 (81,002) (163,000) — (259,641) (183,195) 407,754 224,559

131 (39,119) 411 (7,595) — (3,333) (49,505) 65,021 201,164 266,185

$

Covista Inc. Segment Revenue (unaudited) (in thousands) Three Months Ended September 30, Increase/(Decrease) 2025 $ %

2026 Revenue: Chamberlain Walden Medical and Veterinary Consolidated

$

$

192,400 216,673 102,461 511,534

$

$

179,201 189,960 93,127 462,288

$

$

13,199 26,713 9,334 49,246

7.4 % 14.1 % 10.0 % 10.7 %

Covista Inc. Non-GAAP Financial Measures and Reconciliations We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to nonGAAP reconciliation tables: Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations. Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreignderived income, and loss (income) from discontinued operations. Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, and debt modification costs. Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income. Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures. Net debt – Defined as total long-term debt principal less cash and cash equivalents. Net leverage – Defined as net debt divided by adjusted EBITDA. A description of special items in our non-GAAP financial measures described above are as follows: • Restructuring expense primarily related to workforce reductions and prior real estate consolidations at Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense. • Amortization of acquired intangible assets. • Amortization of cloud computing implementation assets. • Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs. • Loss on debt extinguishment related to the amendment of the Revolver. • Debt modification costs related to refinancing our Term Loan B.

• U.S. tax benefit due to an increase in foreign-derived income. • Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements related to prior divestitures.

Covista Inc. Adjusted Operating Income (unaudited) (in thousands) Three Months Ended September 30, Increase/(Decrease) 2025 $ %

2026 Chamberlain: Operating income Adjusted operating income Operating margin Adjusted operating margin Walden: Operating income Amortization of acquired intangible assets Adjusted operating income

$ $

26,730 $ 26,730 $ 13.9 % 13.9 %

25,608 $ 25,608 $ 14.3 % 14.3 %

1,122 1,122

4.4 % 4.4 %

$

63,649 1,394 65,043

53,269 2,805 56,074

10,380 (1,411) 8,969

19.5 %

5,523 (44) 5,479

33.0 %

12,550 (147) (1,411) 4,547 756 16,295

14.7 %

$

Operating margin Adjusted operating margin Medical and Veterinary: Operating income Restructuring expense Adjusted operating income

$

29.4 % 30.0 %

$ $

Operating margin Adjusted operating margin Covista(1): Operating income (GAAP) Restructuring expense Amortization of acquired intangible assets Strategic advisory costs Debt modification costs Adjusted operating income (non-GAAP)

$

22,251 — 22,251

$

98,027 163 1,394 6,231 756 106,571

Operating margin (GAAP) 19.2 % Adjusted operating margin (non-GAAP) 20.8 % (1) Consolidated results include Home Office activities not allocated to segments.

$

16.0 %

28.0 % 29.5 %

$ $

21.7 % 21.7 %

$

$

16,728 44 16,772

$ $

32.7 %

18.0 % 18.0 %

$

$

85,477 310 2,805 1,684 — 90,276 18.5 % 19.5 %

$

$

18.1 %

Covista Inc. Adjusted EBITDA (unaudited) (in thousands) Three Months Ended September 30, Increase/(Decrease) 2025 $ %

2026 Chamberlain: Adjusted operating income (GAAP) Depreciation Amortization of cloud computing implementation assets Stock-based compensation Adjusted EBITDA (non-GAAP)

$

$

Adjusted EBITDA margin (non-GAAP) Walden: Adjusted operating income (GAAP) Depreciation Amortization of cloud computing implementation assets Stock-based compensation Adjusted EBITDA (non-GAAP) Adjusted EBITDA margin (non-GAAP) Medical and Veterinary: Adjusted operating income (GAAP) Depreciation Amortization of cloud computing implementation assets Stock-based compensation Adjusted EBITDA (non-GAAP)

$

$

$

$

Adjusted EBITDA margin (non-GAAP) Covista(1): Net income (GAAP) Loss (income) from discontinued operations Interest expense Other income, net Provision for income taxes Depreciation and amortization Stock-based compensation Restructuring expense Strategic advisory costs Debt modification costs Adjusted EBITDA (non-GAAP)

26,730 6,094 2,386 2,372 37,582

$

$

$

Adjusted EBITDA margin (non-GAAP) (1) Consolidated results include Home Office activities not allocated to segments.

$

$

1,122 719 859 (198) 2,502

4.4 %

7.1 %

19.5 %

19.6 %

65,043 $ 1,784 2,253 2,782 71,862 $ 33.2 %

56,074 $ 1,940 1,204 2,653 61,871 $ 32.6 %

8,969 (156) 1,049 129 9,991

16.0 %

22,251 2,823 931 1,390 27,395

16,772 2,820 411 1,410 21,413

5,479 3 520 (20) 5,982

32.7 %

5,595 4,825 (1,146) 1,070 2,206 1,583 (112) (147) 4,547 756 19,177

9.0 %

$

$

26.7 %

$

25,608 5,375 1,527 2,570 35,080

67,427 4,055 9,944 (1,416) 18,017 17,826 8,181 163 6,231 756 131,184 25.6 %

$

$

16.1 %

27.9 %

23.0 %

$

$

61,832 (770) 11,090 (2,486) 15,811 16,243 8,293 310 1,684 — 112,007 24.2 %

$

$

17.1 %

Covista Inc. Adjusted Earnings (unaudited) (in thousands, except per share data) Three Months Ended September 30, 2026 2025

Net income (GAAP) $ 67,427 $ 61,832 Restructuring expense 163 310 Amortization of acquired intangible assets 1,394 2,805 Strategic advisory costs 6,231 1,684 Loss on debt extinguishment and debt modification costs 756 295 U.S. tax benefit due to an increase in foreign-derived income (2,031) — Income tax impact on non-GAAP adjustments(1) (2,152) (1,224) Loss (income) from discontinued operations 4,055 (770) Adjusted net income (non-GAAP) $ 75,843 $ 64,932 (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. Three Months Ended September 30, 2026 2025

Diluted earnings per share (GAAP) Effect on diluted earnings per share: Restructuring expense Amortization of acquired intangible assets Strategic advisory costs Loss on debt extinguishment and debt modification costs U.S. tax benefit due to an increase in foreign-derived income Income tax impact on non-GAAP adjustments(1) Loss (income) from discontinued operations Adjusted earnings per share (non-GAAP)

$

1.95 0.00 0.04 0.18 0.02 (0.06) (0.06) 0.12 2.19 34,573

$

1.67 0.01 0.08 0.05 0.01 (0.03) (0.02) 1.75 37,057

$ $ Diluted shares Note: May not sum due to rounding. (1) Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

Covista Inc. Free Cash Flow (unaudited) (in thousands) FY26 Q1 Net cash provided by operating activities-continuing operations (GAAP) Capital expenditures Free cash flow (non-GAAP)

$ $

374,796 $ (55,936) 318,860 $

FY26 Q2

Twelve Months Ended FY26 Q3

427,890 $ (59,880) 368,010 $

406,335 $ (69,872) 336,463 $

FY26 Q4 470,796 $ (77,696) 393,100 $

FY27 Q1 454,438 (99,265) 355,173

Covista Inc. Net Leverage (unaudited) (in thousands) Twelve Months Ended September 30, 2026 Covista: Net income (GAAP) Loss from discontinued operations Interest expense Other income, net Provision for income taxes Depreciation and amortization Stock-based compensation Restructuring expense Strategic advisory costs Debt modification costs Adjusted EBITDA (non-GAAP)

Total long-term debt principal Less: Cash and cash equivalents Net debt (non-GAAP) Net leverage (non-GAAP)

$

$

$ $

257,161 20,634 44,289 (6,108) 79,950 73,836 41,104 6,182 23,109 756 540,913 September 30, 2026 510,000 (222,223) 287,777 0.5x

| October 29, 2026

Share

Share

What to know:

AI can help ease the healthcare workforce gap—if clinicians are trained to use it. According to the Covista Care Capacity Monitor , Covista’s research conducted in partnership with Gallup, 65% of healthcare executives say AI can help address staffing shortages at least somewhat.  Investment in AI technology is growing, but workforce readiness hasn't kept up. Closing the gap between how fast AI is being deployed and how well healthcare workers are prepared to use it is a pressing challenge for health system leaders. 

AI has potential, but staffing remains a top priority

The Covista Care Capacity Monitor found that 76% of healthcare executives already say AI has a somewhat or very positive impact on care quality. However, clinicians have a different focus; only 34% rank improving technology as a major priority for their organization in the next 12 months, while 74% rank achieving adequate staffing as the priority instead. This distinction highlights an important consideration: AI’s promise for improving care is closely tied to the people responsible for delivering it.  

To realize AI’s full potential, healthcare systems must equip the workforce to use and oversee it as a partner rather than a replacement. While the Covista Healthcare Workforce Index found that AI could help close 37% of the 2040 healthcare workforce gap without replacing a single healthcare worker, it can’t build patient trust or execute complex care decisions that are essential to healthcare on its own—that still requires a human connection.  

Where is AI already helping in healthcare? 

Executives report using AI most to reduce administrative burden: 71% for clinical documentation, 54% for electronic health record interactions and 50% for revenue cycle management. Tools like these streamline the work that can pull clinicians away from patients and potentially free up time for more care. Executives see the effect on care quality too: 20% call AI’s impact very positive and 56% call it somewhat positive.  

AI use in healthcare settings is uneven by risk level, and that pattern is instructive for where to invest next. Clinical decision support, the use closest to diagnosis and treatment planning, is deployed less widely than documentation or EHR tools. The closer AI gets to a clinical decision, the more clinicians need training to use it, question it and know when to override it.  

![Technology often used to streamline administrative tasks](https://www.covista.com/sites/g/files/krcnkv471/files/styles/atge_1_1_crop_md/public/2026-10/Technology%20used%20to%20streamline.png?itok=ShHTSpZE)

What are the barriers to AI adoption in healthcare organizations? 

Training gaps, clinician skepticism, limited budgets and trust concerns are key barriers to AI use in healthcare. The technology itself is already being deployed across many administrative workflows but has outpaced the preparation needed to use it well. 

Identifying these barriers is the first step toward getting a real return on AI investment: 

  • Training gaps: 28% of clinicians say they want more training on AI tools or technology, second only to specialty topics in their list of priorities, per the Covista Care Capacity Monitor . However, limited IT bandwidth and fragmented single purpose solutions from multiple vendors make it difficult for organizations to provide the training and support clinicians need. 
  • Clinician skepticism: Only 45% of clinicians believe AI can address staffing shortages at least somewhat, compared to 65% of executives, and just 6% think it could solve the problem mostly or completely, per the report. 
  • Budget constraints: Tight budgets limit how much healthcare systems can invest in AI even when teams are ready to bring it into their workflows. 
  • Trust concerns: Concerns among patients and clinicians about whether to trust AI can limit its impact.  

This is as much a change-management problem as a training one. The data suggests clinicians aren't rejecting AI so much as prioritizing more immediate pressures like staffing, stress and pay, which means AI upskilling has to be built into existing workflows rather than added as one more ask on top of an already stretched schedule. 

How do health systems close the gap between AI deployment and staff readiness? 

Closing the AI readiness gap starts with hiring and training for AI skills by role. Healthcare executives are already thinking this way: 73% say they want physician specialists, nurse practitioners and physician assistants they hire to know how to use AI.  

A physician using AI for diagnostic support needs a different level of fluency than an RN using it for documentation or triage support. Treating AI competency as a single hiring checkbox misses where the actual skill gaps sit. 

Some health systems are addressing this by building AI fluency into the education pipeline itself, rather than retrofitting it after clinicians are hired. As America’s largest healthcare educator, Covista is integrating AI into the classroom through its recent partnership with Google Cloud , which embeds healthcare-specific AI credentialing directly into the curriculum. There has already been strong adoption across nursing, medicine, social work, counseling, veterinary medicine and other disciplines, and graduates are entering the workforce with a foundational knowledge of the AI tools and concepts being used in modern healthcare environments. 

Where this leaves health systems

The next competitive advantage in healthcare AI will come from workforce readiness, not the technology alone. That means AI in healthcare training built into the pipeline, hiring criteria that reflect how each role uses AI and budgets and tracking held to the same rigor as the technology itself. 

Explore the full findings across the Covista Care Capacity Monitor and the Covista Healthcare Workforce Index at  covista.com/research.   

Recent News

Previous

A healthcare worker looking at her iPad.

AI | Covista Care Capacity Monitor

Can AI Help Solve the Healthcare Staffing Shortage?

Two Aspiring Nurse students at their Welcome Ceremony.

Chamberlain University | Covista

SSM Health and Chamberlain: A Partnership Model For The Nursing Shortage

Group of Covista employees from Community Rounds

Covista Open Doors | Covista

Community Rounds: Care In Every Round, Impact In Every Community

Covista Best Employer Wins

Covista Colleagues | AI

Beyond the Badge: A Look Behind Covista's Best Employer Wins

Covista Care Capacity Monitor

Healthcare Salary Gap | Covista Care Capacity Monitor

Examining the Healthcare Salary Gap: Fixing It Will Take More Than a Bigger Paycheck

doctor and two nurses with patient

Chamberlain University | Healthcare Education

Closing the Gap: Chamberlain’s New Campus Targets Utah's Nursing Shortage

Next

Keep reading

Home

233 S. Wacker Drive, Suite 800 
Chicago, IL, 60606 

Covista Logo Mark

Footer


© 2026 Covista Inc. All Rights Reserved

Covista™ is a trademark of Covista Inc. in the United States, European Union, United Kingdom, as well as certain other jurisdictions.

Privacy Policy Cookie Policy Cookie PreferencesAccessibility Governance

Social Media Navigation

Privacy Policy Cookie Policy Accessibility Governance

Social Media Navigation

233 S. Wacker Drive, Suite 800 
Chicago, IL, 60606 

© 2026 Covista Inc. All Rights Reserved

Covista™ is a trademark of Covista Inc. in the United States, European Union, United Kingdom, as well as certain other jurisdictions.

Prompts

Covista Inc. (ticker CVSA), listed in United States.

Company History

Date Change Detail
Feb 6, 2026 Renamed ADTALEM GLOBAL EDUCATION INC. → Covista Inc.
May 24, 2017 Renamed DEVRY EDUCATION GROUP INC. → Adtalem Global Education
Nov 5, 2013 Renamed DEVRY INC → DEVRY EDUCATION GROUP
— Former tickers ATGE

ETFs Holding Covista Inc.

ETF Weight in ETF Shares Market value As of
HDGE short -1.64% -6,000 $ -701.7K Nov 17, 2026
JSML 1.03% 29,835 $ 3.725M Jul 31, 2026
MYLD 0.95% 2,595 $ 323.986K Jul 31, 2026
CGMM 0.78% 241,002 $ 28.376M Nov 16, 2026
JSMD 0.74% 62,173 $ 7.762M Jul 31, 2026
SEIS 0.73% 33,967 $ 4.234M Jun 30, 2026
SYZ 0.55% 3,044 $ 379.465K Jun 30, 2026
FSEG 0.38% 176 $ 21.94K Jun 30, 2026
IVSS 0.25% 533 $ 66.444K Jun 30, 2026
PSC 0.24% 44,826 $ 5.588M Jun 30, 2026
SMDX 0.24% 2,581 $ 303.887K Nov 17, 2026
AVSC 0.23% 62,586 $ 7.369M Nov 16, 2026
DFAT 0.21% 547,881 $ 65.198M Nov 12, 2026
SAGP 0.19% 1,147 $ 142.985K Jun 30, 2026
JMEE 0.17% 41,962 $ 4.907M Nov 17, 2026
RESM 0.16% 48 $ 5,983.68 Jun 30, 2026
DFAS 0.13% 361,018 $ 42.961M Nov 12, 2026
GVLU 0.12% 2,750 $ 323.785K Nov 17, 2026
VFQY 0.12% 4,599 $ 608.586K Aug 31, 2026
GMOV 0.08% 626 $ 82.839K Aug 31, 2026
VFMF 0.07% 5,435 $ 719.214K Aug 31, 2026
WSGE 0.04% 222 $ 25.963K Nov 18, 2026
DXUV 0.04% 19,480 $ 2.318M Nov 12, 2026
MSSM 0.02% 1,312 $ 173.617K Aug 31, 2026
DFUV 0.02% 30,327 $ 3.609M Nov 12, 2026
DFAC 0.02% 164,301 $ 19.552M Nov 12, 2026
DFSV 0.02% 46,898 $ 5.581M Nov 12, 2026
AVSU 0.02% 968 $ 113.972K Nov 16, 2026
FTLS short -0.02% -4,825 $ 0.00 Nov 16, 2026
AVUQ 0.02% 679 $ 79.945K Nov 16, 2026
DCOR 0.02% 68,268 $ 8.124M Nov 12, 2026
DFSU 0.02% 3,155 $ 375.445K Nov 12, 2026
AVUS 0.01% 16,504 $ 1.943M Nov 16, 2026
FESM 0.01% 4,490 $ 559.723K Jun 30, 2026
DFAU 0.01% 8,272 $ 984.368K Nov 12, 2026
DFUS 0.01% 10,937 $ 1.302M Nov 12, 2026
EBI 0.01% 286 $ 37.846K Aug 31, 2026